Literature DB >> 16127708

Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain.

Michael Rigby1, Ruth O'Donnell, Nadia M J Rupniak.   

Abstract

Marked species differences in the distribution of central tachykinin receptors are reported but uncertainty remains about the ability of available ligands to detect NK2 and NK3 receptors in human brain. We compared the distribution of NK1, NK2, and NK3 receptors in sections from rodent, primate, and human brain using the 125I-labeled ligands substance P (SP) for the NK1 receptor, neurokinin A (NKA) for the NK2 receptor, and neurokinin B (NKB) and eledoisin for NK3 receptors. Duration of exposure to autoradiographic film was from 7 days for [125I]SP up to 90 days for the other ligands. High levels of specific [125I]SP binding were seen throughout the brains of all species studied. Specific [125I]NKA binding was detected in brains from neonatal rat, and to a lesser level in adult rat, gerbil, and guinea pig; it was not detected in monkey or human brain, but was present in circular muscle of human duodenum, confirming that this ligand binds to human NK2 receptors under our experimental conditions. Specific [125I]NKB and [125I]eledoisin binding was widespread in brain sections from rats, gerbils, and guinea pigs, and very low levels were also detected in marmoset, squirrel monkey, and rhesus monkey brain after prolonged (up to 90 days) exposure. We failed to identify specific eledoisin binding in human brain, even after prolonged exposures. These findings demonstrate that the NK1 receptor is the predominant tachykinin receptor expressed in primate and human brain, but that low levels of NK3 receptor are present in nonhuman, primate brain. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127708     DOI: 10.1002/cne.20664

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  19 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  [New insights into the pathogenesis and pathophysiology of depression].

Authors:  C Schüle; T C Baghai; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

4.  Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats.

Authors:  Gabriel S Bassi; Ana C Broiz; Margarete Z Gomes; Marcus L Brandão
Journal:  Psychopharmacology (Berl)       Date:  2008-12-18       Impact factor: 4.530

5.  Distinct tachykinin NK(1) receptor function in primate nucleus tractus solitarius neurons is dysregulated after second-hand tobacco smoke exposure.

Authors:  Shin-Ichi Sekizawa; Jesse P Joad; Kent E Pinkerton; Ann C Bonham
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

6.  [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.

Authors:  Cristiana Griffante; Renzo Carletti; Filippo Andreetta; Mauro Corsi
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

7.  TACR1 genotypes predict fMRI response to alcohol cues and level of alcohol dependence.

Authors:  Sara Blaine; Eric Claus; Nicole Harlaar; Kent Hutchison
Journal:  Alcohol Clin Exp Res       Date:  2012-10-18       Impact factor: 3.455

8.  Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.

Authors:  Scott A Heldt; Michael Davis; Emiliangelo Ratti; Mauro Corsi; David Trist; Kerry J Ressler
Journal:  Behav Pharmacol       Date:  2009-10       Impact factor: 2.293

Review 9.  A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.

Authors:  Chenere P Ramsey; Malú G Tansey
Journal:  Exp Neurol       Date:  2013-05-28       Impact factor: 5.330

10.  Increased substance P and synaptic remodeling occur in the trigeminal sensory system with sustained osteoarthritic temporomandibular joint sensitivity.

Authors:  Megan M Sperry; Eric J Granquist; Beth A Winkelstein
Journal:  Pain Rep       Date:  2021-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.